Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991932 | 0.85 | LDHA (0.50) | KDM4ESMN1; SMN2PPARGPPARAFFAR1 | |
| SCHEMBL21991567 | 0.84 | TSHR (0.43) | MAOBALDH1A1 | |
| SCHEMBL21992712 | 0.83 | KDM4E (0.54) | KDM4ESMN1; SMN2MAOBFFAR1LMNA | |
| SCHEMBL21991335 | 0.83 | PPARA (0.55) | NR4A2MAOBPPARGPPARAALDH1A1 | |
| SCHEMBL21991887 | 0.83 | MAPT (0.48) | KDM4EMAOBLMNA | |
| SCHEMBL21991929 | 0.83 | MAPT (0.40) | KDM4ESMN1; SMN2NR4A2MAOBLMNA | |
| SCHEMBL21991983 | 0.83 | MAOB (0.47) | MAOBMMEACECPA1ACE2 | |
| SCHEMBL7178491 | 0.80 | FFAR1 (0.48) | KDM4ESMN1; SMN2NR4A2FFAR1LMNA | |
| SCHEMBL21992007 | 0.80 | PPARA (0.51) | NR4A2PPARGPPARAALDH1A1 | |
| SCHEMBL21991962 | 0.79 | MEN1 (0.46) | MAOBMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | KDM4E 4518/4885SMN1; SMN2 3122/4885NR4A2 1549/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | KDM4E 4518/4885SMN1; SMN2 3122/4885NR4A2 1549/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | KDM4E 4518/4885SMN1; SMN2 3122/4885NR4A2 1549/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | KDM4E 4518/4885SMN1; SMN2 3122/4885NR4A2 1549/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | KDM4E 4518/4885SMN1; SMN2 3122/4885NR4A2 1549/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | KDM4E 4518/4885SMN1; SMN2 3122/4885NR4A2 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.